In July 1997 Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) acquired Avid Corporation. This acquisition will provide Triangle access to a novel protease inhibitor to complement its portfolio of anti-HIV compounds. Triangle was itself subsequently acquired by Gilead (NASDAQ: GILD), itself having been an SBIR-involved firm.
